[1]于家伟,冯兵,曾薇,等.熊去氧胆酸对糖尿病肾病的疗效分析[J].第三军医大学学报,2018,40(20):1870-1875.
 YU Jiawei,FENG Bing,ZENG Wei,et al.Efficacy of ursodeoxycholic acid in treatment of early diabetic nephropathy: report of 40 cases[J].J Third Mil Med Univ,2018,40(20):1870-1875.
点击复制

熊去氧胆酸对糖尿病肾病的疗效分析(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
40卷
期数:
2018年第20期
页码:
1870-1875
栏目:
临床医学
出版日期:
2018-10-30

文章信息/Info

Title:
Efficacy of ursodeoxycholic acid in treatment of early diabetic nephropathy: report of 40 cases
作者:
于家伟冯兵曾薇魏毅王丽敏
陆军军医大学(第三军医大学)第二附属医院肾内科;,河南省人民医院内分泌科
Author(s):
YU Jiawei FENG Bing ZENG Wei WEI Yi WANG Limin

Department of Nephrology, Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037; Department of Endocrinology, Henan Provincial People’s Hospital, Zhengzhou, Henan Province, 450042, China

关键词:
熊去氧胆酸糖尿病肾病尿蛋白/肌酐值肾小球滤过率炎症因子
Keywords:
ursodeoxycholic acid diabetic nephropathy urinary albumin/creatinine ratio estimated glomerular filtration rate inflammatory cytokine
分类号:
R587.1; R692.39; R975.5
文献标志码:
A
摘要:

目的    观察熊去氧胆酸(ursodeoxycholic acid,UDCA)对糖尿病肾病(diabetic nephropathy,DN)Ⅲ期患者的疗效。方法    选择2016年5-12月在陆军军医大学第二附属医院肾内科诊断明确的DNⅢ期微量白蛋白尿期(Mogensen分期Ⅲ期)患者40例,年龄30~59岁,糖尿病病程6个月至30年,采用计算机随机分组方法将患者等分为2组:①厄贝沙坦组,患者口服厄贝沙坦片,0.15 g/d;②UDCA组,患者饭后口服UDCA胶囊,250 mg/d。治疗周期12个月。主要观察指标包括尿蛋白/肌酐值、血肌酐、肾小球滤过率(eGFR),以及血液炎症细胞因子表达变化。结果    至治疗期结束,厄贝沙坦组蛋白肌酐比值下降14.94%,血肌酐下降7.73%,eGFR增加8.64%,与治疗前比较,差异均有统计学意义(P<0.05);UDCA组蛋白/肌酐值下降10.39%,血肌酐下降6.49%,eGFR治疗前后增加7.41%,与治疗前比较,差异均有统计学意义(P<0.05)。两组间比较,各观察指标的差异无统计学意义(P>0.05)。与治疗前比较,厄贝沙坦组患者血浆中CRP、IL-6、TNF-α含量分别降低13.7%、8.7%、5.9%,差异均有统计学意义(P<0.05);与治疗前比较,UDCA组血浆中CRP、IL-6、TNF-α含量分别降低16.2%、14.1%、16.8%,差异均有统计学意义(P<0.05)。两组间比较,血浆中各个炎症细胞因子含量变化的差异无统计学意义(P>0.05)。结论     UDCA可以显著降低DN Ⅲ期患者的尿蛋白/肌酐值,保护肾功能,与厄贝沙坦疗效相当

Abstract:

ObjectiveTo observe the therapeutic effect of ursodeoxycholic acid (UDCA) for patients with early diabetic nephropathy (DN). MethodsFrom May 2016 to December 2016, a total of 40 patients with early DN (Mogensen stage Ⅲ) were diagnosed in the Nephrology Department of Xinqiao Hospital,  aged 30 to 59 years, with the course of disease ranging from 6 months to 30 years, were randomized equally into aprovel group (0.15 g/d) and UDCA group (250 mg/d after meal). The levels of urinary microalbumin, urinary albumin/creatinine ratio, creatinine, and estimated glomerular filtration rate (eGFR), and the contents of inflammatory cytokines in blood and urine were measured or calculated before and in 12 months after treatment, and the results were compared between the 2 groups. ResultsAfter 12 months of treatment, the patients in the aprovel group had the urinary albumin/creatinine ratio reduced by 14.94% and creatinine level by 7.73%, while eGFR increased by 8.64%, and significant differences were noted when compared with the values before treatment (P<0.05). Similar changes were also observed in the UDCA group (10.39%, 6.49% and 7.41%, respectively, P<0.05). But there were no significant differences in above indicators between the 2 groups (P>0.05). Aprovel treatment significantly decreased the serum levels of CRP, IL-6 and TNF-α by 13.7%, 8.7% and 5.9%, respectively, and UDCA also obviously reduced the levels by 16.2%, 14.1% and 16.8%, respectively. But no significant differences were observed between the 2 groups (P>0.05). ConclusionUDCA could decrease the urinary albumin/creatinine ratio, protect renal function and exert similar effects in the patients with stage Ⅲ.

参考文献/References:

[1]杨刚,范秋灵,刘晓丹, 等. 蛋白质组学及其在糖尿病肾病中的应用[J].实用医学杂志,2011, 27(10): 1892-1893.
YANG G, FAN Q L, LIU X D, et al. Proteomics and its application in diabetic nephropathy[J]. J Pract Med,2011, 27(10): 1892-1893.
[2]GRAY S P, COOPER M E. Diabetic nephropathy in 2010: Alleviating the burden of diabetic nephropathy[J]. Nat Rev Nephrol, 2011, 7(2): 71-73. DOI:10.1038/nrneph.2010.176.
[3]XU Y, WANG L, HE J, et al. Prevalence and control of diabetes in Chinese adults[J]. JAMA, 2013, 310(9): 948-959. DOI:10.1001/jama.2013.168118.
[4]SONG M K, DAVIES N M, ROUFOGALIS B D, et al. Management of cardiorenal metabolic syndrome in diabetes mellitus: a phytotherapeutic perspective[J]. J Diabetes Res,2014,2014:313718. DOI:10.1155/2014/313718.
[5]ROSCIONI S S, HEERSPINK H J, DEZEEUW D. The effect of RAAS blockade on the progression of diabetic nephropathy[J]. Nat Rev Nephrol, 2014, 10(2):77-87. DOI:10.1038/nrneph.2013.251.
[6]陈吉刚,庞琦,曾薇, 等.甜菜碱对糖尿病肾病小鼠的治疗作用及其机制[J].第三军医大学学报,2012,34(11): 1040-1043.
CHEN J G, PANG Q, ZEGN W, et al. Therapeutic effect of betaine on diabetic nephropathy in db/db mice[J].J Third Mil Med Univ,2012,34(11):1040-1043.
[7]LIU J, YANG J R, CHEN X M, et al. Impact of ER stressregulated ATF4/p16 signaling on the premature senescence of renal tubular epithelial cells in diabetic nephropathy[J]. Am J Physiol Cell Physiol, 2015, 308(8): C621-C630. DOI:10.1152/ajpcell.00096.2014.
[8]LI J, WANG J J, ZHANG S X. Preconditioning with endoplasmic reticulum stress mitigates retinal endothelial inflammation via activation of xbox binding protein 1[J]. J Biol Chem, 2010,286(6):4912-4921. DOI:10.1074/jbc.m110.199729.
[9]GAO X, FU L, XIAOM,et al. The nephroprotective effect of tauroursodeoxycholic acid on ischaemia/reperfusioninduced acute kidney injury by inhibiting endoplasmic reticulum stress[J].Basic Clin Pharmacol Toxicol, 2012,111(1): 14-23. DOI:10.1111/j.17427843.2011.00854.x.
[10]TANG C H, RANATUNGA S,KRISS C L,et al. Inhibition of ER stressassociated IRE1/XBP1 pathway reduces leukemic cell survival[J].J Clin Invest, 2014, 124(6): 2585-2598. DOI:10.1172/JCI73448.
[11]吴丽婷,刘梦琼.胱抑素C联合eGFRMDRD诊断早期DN的研究[J].中国免疫学杂志,2015,31(10):1394-1396,1399. DOI:10.3969/j.issn.1000484X.2015.10.021.
WU L T, LIU M Q. Studies of cystatin C joint eGFRMDRD for diagnosis of early DN[J]. Chin J Immunol, 2015,31(10):1394-1396,1399.DOI:10.3969/j.issn.1000484X.2015.10.021.
[12]PALMER S C, MAVRIDIS D, NAVARESE E, et al. Comparative efficacy and safety of blood pressurelowering agents in adults with diabetes and kidney disease: a network metaanalysis[J]. Lancet, 2015,385(9982):2047-2056. DOI:10.1016/S01406736(14)624594.
[13]HOTAMISLIGIL G S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease[J]. Cell, 2010, 140(6): 900-917. DOI:10.1016/j.cell.2010.02.034.
[14]CUNARD R. Endoplasmic reticulum stress in the diabetic kidney, the good, the bad and the ugly[J]. J Clin Med,2015, 4(4): 715-740. DOI:10.3390/jcm4040715.
[15]DELEPINE M, NICOLINO M, BARRETT T, et al. EIF2AK3, encoding translation initiation factor 2α kinase 3, is mutated in patients with WolcottRallison syndrome[J]. Nat Genet, 2000,25(4):406-409. DOI: 10.1038/78085.
[16]MADHUSUDHAN T, WANG H, DONG W, et al.Defective podocyte insulin signalling through p85XBP1 promotes ATF6dependent maladaptive ERstress response in diabetic nephropathy[J]. Nat Commun, 2015, 6: 6496. DOI: 10.1038/ncomms7496.
[17]RUILOPE L M,MALACCO E,KHDER Y,et al.Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors:The VAST study[J]. Clin  Ther, 2005, 27(5): 578-588. DOI:10.1016/j.clinthera.2005.05.006.
[18]黄欣,许冬梅.肾病药物治疗学[M].北京:化学工业出版社,2010:209-210.
HUANG X, XU D M. Nephrotictherapy[M]. Beijing: Chemical Industry Press,2010:209-210.
[19]吴泽成, 刘慎微. 缬沙坦对2型糖尿病模型大鼠肾组织巨噬细胞浸润的影响[J]. 医药导报, 2008, 27(3): 268-271.
WU Z C, LIU S W. Effect of valsartan on macrophage infiltration in renal tissue of type 2 diabetic rats[J]. Herald Med,2008,27(3): 268-271.
[20]CAO A, WANG L, CHEN X, et al. Ursodeoxycholicacid ameliorated diabetic nephropathy by attenuating hyperglycemiamediated oxidative stress[J]. Biol Pharm Bull, 2016, 39(8): 1300-1308. DOI:10.1248/bpb.b1600094.
[21]VANG S, LONGLEY K, STEER C J, et al. The unexpected uses of ursoand tauroursodeoxycholicacid in the treatment of nonliver diseases[J]. Glob Adv Health Med, 2014, 3(3): 58-69. DOI:10.7453/gahmj.2014.017.
[22]MIN J H, HONG Y H, SUNG J J, et al. Oral solubilized ursodeoxycholic acid therapy in amyotrophic lateral sclerosis: a randomized crossover trial[J]. J Korean Med Sci, 2012, 27(2): 200-206. DOI:10.3346/jkms.2012.27.2.200.
[23]PARVING H H, CHATURVEDI N, VIBERTI G, et al. Does microalbuminuria predict diabetic nephropathy[J]. Diabetes Care, 2002, 25(2): 406-407. DOI:10.2337/diacare.25.2.406.

相似文献/References:

[1]童强,周厚地,段炼,等.硫辛酸在糖尿病早期肾病治疗中的临床疗效观察[J].第三军医大学学报,2012,34(21):2224.
[2]魏倩萍,邓华聪,赵劼.p38MAPK对大鼠肾小球系膜细胞表达PPAR-γ的影响[J].第三军医大学学报,2006,28(16):1659.
[3]杨孟雪,甘华,沈清,等.1, 25-(OH)2D3及LPS对2型糖尿病肾病尿毒症患者单核细胞维生素D受体表达的影响[J].第三军医大学学报,2011,33(16):1731.
 Yang Mengxue,Gang Hua,Sheng Qing,et al.Effect of 1,25-(OH)2D3 and LPS on expression of vitamin D receptor in human monocytes incubated with sera from type 2 diabetes patients and diabetic nephropathy patients with uremia[J].J Third Mil Med Univ,2011,33(20):1731.
[4]魏倩萍,邓华聪,赵劼,等.亚硒酸钠对大鼠肾小球系膜细胞HBZY-1单核细胞趋化蛋白-1 mRNA表达的影响[J].第三军医大学学报,2005,27(14):1446.
[5]魏平,梁瑞凯,谭明红,等.2型糖尿病肾病大鼠肾脏MCP-1与氧化应激相关性研究[J].第三军医大学学报,2011,33(19):2021.
 Wei Ping,Liang Ruikai,Tan Minghong,et al.Correlation on renal MCP-1 and oxidative stress in rats with type 2 diabetic nephropathy[J].J Third Mil Med Univ,2011,33(20):2021.
[6]谭明红,陈兵.水化治疗对糖尿病肾病患者对比剂肾病的预防作用[J].第三军医大学学报,2011,33(20):2184.
 Tan Minghong,Chen Bing.Preventive effect of hydration therapy on contrast-induced nephropathy in diabetic nephropathy patients[J].J Third Mil Med Univ,2011,33(20):2184.
[7]张政,罗勇军,彭惠民,等.早期糖尿病肾病相关微小RNA在小鼠肾脏的表达变化[J].第三军医大学学报,2010,32(13):1383.
 Zhang Zheng,Luo Yongjun,Peng Huimin,et al.Expression of early diabetic nephropathy-related microRNA in kidneys of diabetic mice[J].J Third Mil Med Univ,2010,32(20):1383.
[8]毛春谱,李小毅,李伟.参芪降糖颗粒对早期糖尿病肾病患者血清TGF-β1、VEGF的影响[J].第三军医大学学报,2010,32(13):1475.
[9]杜飞,高原,姚君,等.灯盏花素对高糖环境近端小管上皮细胞钠钾ATP酶活性的影响[J].第三军医大学学报,2008,30(23):2242.
[10]梁瑞凯,魏平.普罗布考治疗46例糖尿病肾病的疗效观察[J].第三军医大学学报,2011,33(08):849.
 Liang Ruikai,Wei Ping.Observation of the therapeutic effect of probucol on 46 cases of diabetic nephropathy[J].J Third Mil Med Univ,2011,33(20):849.

更新日期/Last Update: 2018-11-01